CSL Limited (CSL.AX)

Compare

273.47

+0.99

+(0.36%)

As of 10:23:11 AM GMT+11. Market Open.

BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

BMRN vs. CSLLY: Which Stock Is the Better Value Option?

Zacks yesterday

CSL.AX
+0.36%
BMRN
Is CSL Limited (ASX:CSL) Trading At A 30% Discount?

Key Insights CSL's estimated fair value is AU$408 based on 2 Stage Free Cash Flow to Equity CSL is estimated to be 30...

Simply Wall St. 18 days ago

CMXHF

CSLLY
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorization for garadacimab as a once-monthly prophylactic treatment for hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. Garadacimab is a monoclonal antibody that targets activated factor XII (factor XIIa), a plasma protein that plays

PR Newswire last month

CMXHF

CSLLY
CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform

SAN FRANCISCO, December 09, 2024--In 2023, the life sciences industry experienced a 13% year-over-year increase in digital experiences, outpacing the global average by 5 percentage points, according to the 2024 Life Sciences Digital Engagement Benchmarks Report. This growth reflects the life sciences industry's increasing focus on omnichannel strategies to engage healthcare professionals (HCPs). Today, ON24 (NYSE: ONTF), a leading intelligent engagement platform, announced that CSL Behring, a gl

Business Wire last month

ONTF

CMXHF

CSLLY
EXEL vs. CSLLY: Which Stock Is the Better Value Option?

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 2 months ago

CSL.AX
+0.36%
EXEL
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 2 months ago

CSL.AX
+0.36%
EXEL
Should Weakness in CSL Limited's (ASX:CSL) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

It is hard to get excited after looking at CSL's (ASX:CSL) recent performance, when its stock has declined 5.3% over...

Simply Wall St. 2 months ago

CMXHF

CSLLY
EXEL or CSLLY: Which Is the Better Value Stock Right Now?

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

Zacks 3 months ago

EXEL

CSLLY
New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza

CSL Seqirus, a business of CSL (ASX: CSL), today announced the first season (2023-2024 influenza season) results of the first pragmatic randomized study to evaluate the relative vaccine effectiveness (rVE) of adjuvanted inactivated influenza vaccine (aIIV) compared to high-dose inactivated influenza vaccine (HD-IIV) for prevention of lab-confirmed influenza. Results for the first season demonstrated that adjuvanted and high-dose influenza vaccines did not differ in effectiveness against Polymera

PR Newswire 3 months ago

CMXHF

CSLLY
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). “FILSPARI targe

GlobeNewswire 3 months ago

TVTX

CMXHF

CSLLY
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).

CNW Group 3 months ago

CMXHF

CSLLY

TVTX
CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines

CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from five studies reinforcing the importance of seasonal influenza vaccination and exhibiting the benefits of cell-based influenza vaccines among people aged 6 months to 64 years. These studies will be presented this week at the IDWeek 2024 conference taking place in Los Angeles, California from October 16-19, 2024.

PR Newswire 3 months ago

CMXHF

CSLLY
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of bird flu vaccines. According to the Centers for Disease Control and Prevention, bird flu was detected in 254 dairy herds across 14 states. Including the most recent two cases in California, 16 human cases of H5 have been reported in the United States during 2024, bringing the total to 17 cases since 202

Benzinga 3 months ago

SNY

GSK

CSL.AX
+0.36%
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza

CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS). This latest acquisition of pre-pandemic vaccine will further supplement BARDA's stockpile of vaccine

PR Newswire 3 months ago

CMXHF

CSLLY
CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations

CSL Seqirus, a business of CSL (ASX: CSL), today announced data from a range of real-world evidence (RWE) studies, highlighting the important role influenza vaccination plays in protecting public health. The data are being presented in an oral presentation and poster sessions at OPTIONS for the Control of Influenza (OPTIONS XII), being held in Brisbane, Australia from September 29 to October 2, 2024.

PR Newswire 3 months ago

CMXHF

CSLLY
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying (sa-mRNA) COVID-19 vaccine, compared to Pfizer Inc’s (NYSE:PFE) shot Comirnaty. The study showed that the sa-mRNA COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other variants, and at one-sixth the dose of the comparator (5 μg v

Benzinga 3 months ago

ARCT

PFE

CSL.AX
+0.36%
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

WALTHAM, Mass. & SAN DIEGO, September 30, 2024--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and self-amplifying messenger RNA (sa-mRNA) pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a head-to-head study demonstrating that self-amplifying (sa-mRNA) COVID-19 vaccine maintained superior immunogenicity compared to the conventional mRNA vaccine Comirnaty® for up to one year against Wuhan-Hu-1, Omicron BA.4-5 and certain other variants, and at one-sixth the dos

Business Wire 3 months ago

CMXHF

CSLLY

ARCT
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak

CSL Seqirus, a business of CSL (ASX: CSL), announced today that through its public-private partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), the company will expand its Vendor Managed Inventory (VMI) program for its proprietary MF59® adjuvant. This decision will further support the U.S. government's pandemic preparedness effor

PR Newswire 4 months ago

CMXHF

CSLLY
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

CSL Vifor today announced that Japan's Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria Pharmaceutical Co., Ltd. (Zeria), marketing authorization approval for Veltassa® for the treatment of adult patients with hyperkalemia, a condition characterized by high levels of potassium in the blood. Veltassa® has now received marketing authorizations in 41 countries worldwide.

PR Newswire 4 months ago

CMXHF

CSLLY
CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

CSL (ASX:CSL) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a 25% increase in net profit after tax and innovative product launches, juxtaposed against near-term market growth difficulties and inflationary pressures.

Simply Wall St. 4 months ago

CMXHF

CSLLY

Performance Overview

Return	CSL.AX	S&P/ASX 200 [XJO]
YTD	-2.88%	+3.39%
1-Year	-5.39%	+11.65%
3-Year	+10.31%	+20.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CSL Limited (CSL.AX)

BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

Is CSL Limited (ASX:CSL) Trading At A 30% Discount?

CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform

EXEL vs. CSLLY: Which Stock Is the Better Value Option?

EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?

Should Weakness in CSL Limited's (ASX:CSL) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

EXEL or CSLLY: Which Is the Better Value Stock Right Now?

New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report

CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza

CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Performance Overview